Introduction: Russia is the largest medical device market in the Eurasian region and a typical “high barrier, long timeline” destination for manufacturers expanding overseas. Russia is currently at a critical window in which national registration (RZN) and Eurasian Economic Union registration (EAEU) run in parallel, with a gradual transition toward the single Union route – under the amending protocol signed on 29 December 2025, the national procedure will stop accepting first registration applications after 31 December 2027, after which new registrations can only follow the Union route. Choosing the wrong route can mean millions in investment and more than a year of lost time. This article systematically compares the two routes, the document system, timelines and frequent pain points, as a decision reference for prospective applicants.
I. Regulatory Framework: Who Regulates and Under What Rules
The competent authority for medical devices in Russia is the Federal Service for Surveillance in Healthcare (Roszdravnadzor, abbreviated RZN), which handles registration acceptance, technical review, registration decisions and registry entries, and post-market surveillance (adverse events, inspections, recalls). Technical review is carried out by expert institutions under RZN (including FSBI “VNIMT” and FSBI “NIK”). The core legal framework includes:
- Article 38 of the Fundamentals of Legislation of the Russian Federation on the Protection of Citizens’ Health (Federal Law No. 323-FZ of 21 November 2011);
- Government Decree No. 1684 on National Registration Rules for Medical Devices (30 November 2024, effective 1 March 2025, replacing the former Decree No. 1416 of 27 December 2012; applications submitted before 1 March 2025 remain governed by Decree No. 1416);
- Ministry of Health Order No. 421n (13 May 2026) on the procedures for conformity assessment of medical devices in the form of technical tests, toxicological studies and clinical trials, effective 1 September 2026 and valid until 1 September 2032, replacing the former Order No. 885n (30 August 2021);
- Government Decree No. 135 (production inspection rules) and Decree No. 136 (quality management system requirements), both dated 9 February 2022;
- Ministry of Health Order No. 540n (safety monitoring procedures) and Order No. 541n (adverse event reporting procedures), both dated 26 May 2026, effective 1 September 2026;
- RZN Order No. 750 (19 August 2026) on the Administrative Regulation of the State Service for Medical Device Registration, valid until 31 December 2028;
- Under the EAEU framework: the Agreement on Common Principles and Rules for the Circulation of Medical Devices (Medical Products and Medical Equipment) in the Eurasian Economic Union (23 December 2014) and Decision No. 46 of the Council of the Eurasian Economic Commission (12 February 2016) on the Registration and Expert Review Rules for the Safety, Quality and Effectiveness of Medical Devices.
One institutional change requires particular attention: Decree No. 1684 changed the registration outcome from “issuing a paper registration certificate” to “entering a record in the national register”, and RZN Order No. 750 further clarifies that no separate paper certificate or separate notification is issued; the registration decision is evidenced by the registry record. The “certificate” companies request is in fact a registry extract, and tender and customs clearance documents should be prepared accordingly.
Russia classifies devices by risk into Class 1, 2a, 2b and 3 (low, medium, higher and high risk respectively; classification is based on Ministry of Health Order No. 4n (6 June 2012) on Device Classification and the classification nomenclature, structurally aligned with the EAEU four-tier framework but not item-for-item identical, so CE or FDA classification conclusions cannot be carried over directly). Classification is determined by the applicant under the above rules and verified by the expert institution during review; where the nomenclature does not cover the device or the class is in doubt, the official route is to apply for a classification determination. Once classification is wrong, the entire dossier and test plan must be redone – this is the most frequent source of rework in Russian projects.
II. Route Selection: RZN National Registration vs EAEU Union Registration
Route One: RZN National Registration
Covers the Russian market only. The registration outcome is confirmed as a national register record with no fixed validity period, no expiry-based renewal, and relatively low certificate maintenance cost. Technical files are mainly in Russian, and review criteria align with Russian local clinical practice. Official review timelines: 31 working days without clinical trials; 50 working days with clinical trials (both excluding the time consumed by testing, clinical trials and production inspections themselves). Typical total timeline: Class 1, 6-9 months; Class 2a, 8-12 months; Class 2b and Class 3, 10-15 months. Class 1 and Class 2a (non-sterile) follow a relatively simplified process and do not require a production site inspection.
Route Two: EAEU Union Registration
One registration under Route Two covers the “reference state plus the recognizing states listed in the application”; there must be at least 1 recognizing state and at most 4 besides the reference state (the Union has 5 member states: Russia, Belarus, Kazakhstan, Kyrgyzstan and Armenia). Member states not listed in the application are not covered, and mutual recognition procedures would be required – it is not “one registration automatically valid in all five states”. The registration certificate likewise has no fixed validity period (certificates issued under Union rules carry no expiry date) and no 5-year renewal, but Class 2a (sterile), Class 2b and Class 3 must undergo a production site inspection before the expert conclusion is issued, and post-certification inspection control must also be accepted; no “annual surveillance audit of certificates” arrangement exists in Union rules. Documents must comply with Union common standards and be submitted in Russian (additional translation is needed if recognizing states require their national language). Typical total timeline: Class 1, 10-12 months; Class 2a (non-sterile), 12-20 months; Class 2a (sterile), 15-24 months; Class 2b and Class 3, 18-30 months, with individual cases involving multi-center clinical trials and production inspections exceeding 30 months. Costs are higher than national registration.
Clarification of a common confusion: the “5-year validity” refers to the EAC declaration of conformity (a conformity declaration used for customs clearance, valid for up to 5 years), not the medical device registration certificate. Registration certificates (national and Union routes alike) carry no expiry date, but they can be revoked, suspended, or invalidated for failure to fulfill post-market obligations.
Key dates (must be built into the project schedule):
| Date | Milestone |
|---|---|
| 2025-12-29 | Member states signed the protocol amending the Agreement on Common Principles and Rules for the Circulation of Medical Devices, extending the transition period; it was provisionally applied 10 days after signing, and takes formal effect once all member states complete domestic ratification (ratification was still in progress as of this update; Belarus completed ratification in June 2026) |
| 2026-09-01 | Ministry of Health Order No. 421n (new testing and clinical procedures) and Orders No. 540n/541n (safety monitoring and adverse event reporting) take effect |
| 2027-03-01 (planned) | The new expert review procedure for quality, effectiveness and safety is planned to take effect (draft, replacing Order No. 206n), planned to remain valid until 31 December 2028 |
| 2027-09-01 | Deadline for foreign manufacturers to complete authorized representative information updates, and the effective date of the provision on revoking registrations for failure to update on time (Decree No. 974, 3 August 2026, previously 1 September 2026) |
| 2027-12-31 | Deadline for accepting first registration applications under the national procedure (applications already accepted continue to be processed) |
| From 2028-01-01 | New registrations can in principle only follow the EAEU Union route |
| 2028-12-31 | Re-registration and registration document changes for products already holding national registration certificates can still be handled under the national procedure until this date |
The division between 31 December 2027 and 31 December 2028 (first-application deadline vs change/re-registration deadline) follows the final text of the protocol and each member state’s implementing documents; re-verify the latest versions published by RZN and the Eurasian Economic Commission before project initiation.
Decision guidance: since the certificates under both routes have no expiry date, the selection logic is no longer “certificate length” but three points: (1) market scope (Russia only, or also Kazakhstan, Belarus, Armenia and Kyrgyzstan); (2) the change channel after 2028 (whether national certificates can be smoothly changed from 2029 remains to be seen; Union certificates carry no such concern); (3) the inspection and clinical burden for high-risk devices. Accordingly: for medium- and low-risk devices targeting Russia alone within three years, seize the national procedure window; for multi-country Eurasian expansion plans, or Class 2b/3 devices with long life cycles, build the dossier directly to EAEU standards to avoid a second round of investment.
III. Application Dossier: Russian Language and Local Testing Are Hard Thresholds
1. Entity and Authorization
Foreign manufacturers cannot apply directly; a local Russian authorized representative (the applicant) must submit the application and bear local regulatory responsibility. The power of attorney (POA) must be notarized and apostilled and translated into Russian. Decree No. 1684 requires the authorized representative information in the dossier to remain valid at all times: where representative documents expire or change without timely update, RZN has the right to revoke the registration. The effective date of this revocation provision was postponed by Decree No. 974 (3 August 2026) to 1 September 2027, but the obligation itself has not been relaxed. In practice this is the most common cause of existing certificates becoming invalid; set expiry reminders in internal registers.
2. Technical Documents
Product information, R&D and manufacturing materials, the risk management report (ISO 14971), existing test reports, product photographs, etc., are prepared in the format required by RZN, all translated into Russian and notarized. Decree No. 1684 sets explicit photo requirements: color photographs no smaller than 18×24 cm, covering labeling and packaging (foreign product packaging labels must carry Russian-language information), and for software-containing devices, color images of the software interface and electronic media; also required, where applicable, are a description and draft methodology for type approval of measuring instruments, proof of trademark usage rights, proof of registration of the foreign manufacturer, and similar items.
3. Local Testing
Samples must be sent to testing institutions holding the relevant accreditation scope in the national accreditation system for technical tests, toxicological studies (a component of technical tests at the electrical safety and electromagnetic compatibility layer, not a separate step) and clinical evaluation (human clinical trials where necessary). This is the biggest difference between Russia and other markets: foreign reports cannot replace local testing. Under Order No. 421n: the testing institution completes document review within 10 working days; technical tests take 30 working days, extendable once by a further 20 working days; results are issued in the form of technical test reports and toxicological study reports (the former “assessment conclusion” format has been abolished), can be issued electronically and entered into the RZN information system. From 1 September 2026, reagents, kits, control materials, calibrators, wash solutions, diluents, culture media and certain plastic consumables among in vitro diagnostics are exempt from technical tests.
4. Quality System
The quality system must comply with ISO 13485/GOST R ISO 13485 (currently GOST ISO 13485-2017); under Decrees No. 135 and No. 136 (both dated 9 February 2022), sterile Class 2a, Class 2b and Class 3 products must undergo a factory audit (production site inspection), and from 1 January 2024 the registration dossier must already contain the inspection report; an ISO 13485 certificate cannot substitute for it. Inspections are conducted only by two institutions under RZN, VNIMT and NIK, and take about 90 working days in total; it is advisable to apply 3-4 months before the planned dossier submission. Class 1 and non-sterile Class 2a are not mandatory, but for products that have already been inspected, changes filed within the report’s validity period can be handled through the notification route.
5. Labeling and Instructions for Use
Russian-language labeling and instructions for use, with content consistent with the intended use as filed.
6. Clinical Data
Class 1 devices can usually complete clinical evaluation based on literature and existing data. Order No. 421n specifies the statutory circumstances in which human clinical trials are mandatory (the registered product is a new type within its classification, adopts a new and complex medical technology, uses new materials that contact the human body with unstudied biological effects, claims expanded indications, or safety and effectiveness cannot be confirmed through clinical data analysis, etc.). Class 2b and Class 3 devices mostly require clinical data. One common misconception must be corrected: foreign human clinical trial data cannot in principle substitute for clinical trials within Russia; trials must be conducted in Russian-approved medical institutions after ethics review. Foreign data and literature serve only the “clinical evaluation” step – experts may use them to reduce trial scale, but they cannot exempt the local trial.
Special channels (narrow applicability, verify case by case): besides the regular route, there are simplified registration for shortage/defect-risk devices under Decree No. 552, and series (batch) registration, among other special cases. Such channels impose strict limits on the product, quantities and validity period and cannot be used as a routine strategy.
IV. Common Difficulties and How to Respond
Difficulty One: Local Testing Scheduling
Accredited laboratory capacity is limited, and testing is often the single largest uncertainty in the whole timeline. Response: prepare documents and samples in parallel and submit test applications as early as possible. Also note the 1 September 2026 cutoff – applications already submitted to testing institutions or medical institutions before that date are completed under the old Order No. 885n procedure, while those submitted after are governed by Order No. 421n; the application strategy should be locked in before the submission date.
Difficulty Two: Translation Quality
Russian translations of technical files and instructions for use are a frequent source of expert queries. Response: use Russian technical translators with medical device regulatory experience and build a unified terminology database.
Difficulty Three: Factory Audit Preparation
Site audits for sterile and high-risk products may add months due to auditor scheduling (only two inspection institutions exist, so queuing effects are significant). Response: complete internal system self-checks and document-executability verification early.
Difficulty Four: Recognizing State Objections (EAEU Route Only)
After the reference state issues its conclusion, each recognizing state still has room to review and raise objections; once a state raises safety concerns, supplementary documents or even supplementary testing may be triggered – an extra timing risk the Union route carries compared with the national route. Response: at the application stage, converge the recognizing-state list down to the countries where you will actually sell; do not treat “listing broadly” as a placeholder.
Difficulty Five: Certificate Ownership and Control
If the registration is held in a distributor’s name, channel changes create a “certificate-holder separation”. Response: specify registration ownership, termination handover and dossier access rights in the POA and agreements.
Timeline judgment: about 14 months remain until the national procedure application deadline (31 December 2027), and application volume will be released intensively in the second half of 2027. From that point on, progress will be decided not by document quality but by queue position – testing institution slots, production inspection scheduling, and recognizing-state confirmation order all need early booking.
V. Post-Market Obligations
After certification, ongoing obligations include: adverse event and product defect reporting, operation of a post-market surveillance (PMS) system, post-market safety monitoring reports, registration changes for major changes, and cooperation with RZN inspections of the authorized representative or production sites.
New reporting obligations from 1 September 2026: Ministry of Health Order No. 541n requires adverse events discovered in circulation to be reported through the RZN automated information system within 20 working days of discovery, and the reporting obligation extends from the manufacturer to “the party that discovers the event” (authorized representatives, suppliers, sellers, medical institutions, etc. may all become reporters); Order No. 540n unifies the collection, processing, recording and analysis requirements for safety monitoring. Note: Order No. 540n does not apply to devices registered under EAEU rules; such products follow Union-level monitoring rules – meaning the same company’s post-market obligations differ between the two routes, and the same SOP cannot be applied to both. One further clarification: “PSUR (Periodic Safety Update Report)” is a pharmaceutical regime; medical devices should be described under the monitoring and reporting systems above.
Closing: the success or failure of a Russia project is often decided at the initiation stage – choosing the right route, classifying correctly, booking testing early, and writing the entity structure into contracts. With these four things done solidly, the registration timeline can be called controllable.
Disclaimer: This article is compiled from public regulations and official information of the Government of the Russian Federation, RZN and the Eurasian Economic Commission (regulations verified as of 30 October 2026) and does not constitute legal advice. Russian and EAEU regulations are updated frequently, and documents involving transition arrangements are still in the ratification process. For specific products, classification, test items and transition applicability must follow the latest decisions of the Russian competent authorities and the Eurasian Economic Commission and case-specific official approvals.